

The Root Cause Medicine Podcast
Rupa Health
In each episode, we’ll meet renowned medical experts, specialists and pioneers who’ve influenced the way certain conditions and diseases are understood and treated. We focus on giving you the information you need to understand the root cause, symptoms and treatments available for specific medical conditions.
Episodes
Mentioned books

Nov 19, 2026 • 27min
Probiotic Quality Testing: Strains, CFUs, and Shelf Life
Dr. Holly Lucille welcomes Ellie Abrams, PhD, from Fullscript’s Quality team to the Root Cause Medicine Podcast. They explore identity, potency, storage, and label claims.Clinical TakeawaysStart with strain-specific evidence. Abrams emphasizes matching the strain and studied amount to the intended outcome. A higher colony-forming unit (CFU) count alone does not establish a better product. (ODS 2025)Separate identity from potency. The episode distinguishes organism identification from enumeration, which measures quantity. (Jackson 2019) Neither test alone establishes clinical benefit.Ask about viability through expiration. Abrams highlights finished-product testing and stability data. Raw-material results alone do not demonstrate that the labeled amount remains viable throughout shelf life. (Fenster 2019)GuestEllie Abrams, PhD, works on Fullscript’s Quality team. Her Penn State doctorate is in plant biology, with expertise in analytical chemistry, supplement authentication, and quality testing.Clinician FAQ1. What should clinicians look for on a probiotic label?Look for strain identification, CFUs per serving, expiration date, and storage instructions, plus research relevant to the intended use. (ODS 2025)2. Does a higher CFU count mean a better probiotic?Abrams emphasizes the studied strain, amount, and intended outcome rather than comparing products by total CFUs alone. (ODS 2025)3. How are probiotic identity and potency tested?Abrams describes genetic identification and plate counts for CFUs. Flow cytometry measures cells differently and does not directly report CFUs. (Jackson 2019)4. What is probiotic overage?Overage is surplus material added during manufacturing to account for losses in viable organisms. Stability data should support shelf-life claims. (Fenster 2019)5. Are probiotic gummies and beverages equivalent to capsules?Format alone does not establish equivalence. Abrams discusses heat and moisture challenges and scrutiny of strain stability, protective technology, and testing. (Fenster 2019)Key Moments03:56 Identity testing and strain specificity07:36 Reading labels and interpreting CFUs12:12 Storage conditions and expiration dates14:04 Survival testing and probiotic overage15:59 Gummies, beverages, and formulation challenges21:55 Questions to ask manufacturers23:45 Fullscript’s product review and testingDisclaimerThe views expressed on this podcast are those of the hosts and the guests, and they don't necessarily reflect the views of FullScript or any affiliated organizations. This podcast is for informational and educational purposes only, and it's not intended to be medical advice. For your safety, always check with your healthcare provider before making any changes to your healthcare routine.ReferencesFenster, K., Freeburg, B., Hollard, C., Wong, C., Rønhave Laursen, R., & Ouwehand, A. C. (2019). The production and delivery of probiotics: A review of a practical approach. Microorganisms, 7(3), 83. https://doi.org/10.3390/microorganisms7030083Jackson, S. A., Schoeni, J. L., Vegge, C., Pane, M., Stahl, B., Bradley, M., Goldman, V. S., Burguière, P., Atwater, J. B., & Sanders, M. E. (2019). Improving end-user trust in the quality of commercial probiotic products. Frontiers in Microbiology, 10, 739. https://doi.org/10.3389/fmicb.2019.00739Office of Dietary Supplements. (2025). Probiotics: Fact sheet for health professionals. National Institutes of Health. https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/

Nov 12, 2026 • 1h 6min
He Built the “MRI for the Microbiome”. Now Everyone Can Access It.
Host Kate joins Leo Grady, PhD, founder and CEO of Jona, to explore AI-assisted microbiome analysis, shotgun sequencing, and personalized nutrition. Inspired to build Jona after his son suffered from severe gut issues that kept him out of school—and is now healthy—Grady explains how the platform processes the equivalent of 8 MRIs worth of data per test. They also discuss digital-twin simulations, research transparency, and translating complex stool-test data into clinician-reviewed plans.GuestLeo Grady, PhD, is Jona’s founder and CEO. His background includes AI applications in radiology, cardiovascular assessment, and pathology at Siemens, HeartFlow, and Paige AI.Key TakeawaysAI microbiome analysis moves beyond species counts. Learn how combining shotgun sequencing with published clinical research maps functional potential and complex microbial patterns. (Quince 2017)Digital-twin technology informs clinician-led care. Explore how predictive simulations model response to targeted nutrition and personalized supplements while keeping practitioners in control. (Diener 2020) (Porcari 2025)Shotgun sequencing delivers deep functional insights. Discover how processing extensive stool-sequencing datasets translates complex microbial metabolic capacity into actionable clinical guidance. (Quince 2017)Clinical FAQ1. How does AI-assisted gut microbiome testing analyze stool samples?Shotgun sequencing data is compared against published human clinical studies using advanced AI algorithms to detect microbial patterns and summarize functional potential. (Quince 2017)2. What is a gut microbiome digital twin and how is it used?A microbiome digital twin is a computational simulation that predicts potential shifts in microbial activity following dietary, lifestyle, or targeted supplement interventions. (Diener 2020)3. Can AI microbiome testing replace standard clinical diagnosis?No. Stool testing and AI models provide functional insights but do not replace validated diagnostic tools or practitioner oversight. (Porcari 2025)Timestamps02:57 Grady’s AI and healthcare background11:39 Why he founded Jona (his son's severe gut health journey and recovery)22:20 Health domains and report structure30:09 Functional capacity versus blood measurements36:17 Digital-twin simulations55:16 Sequencing workflow and evidence reviewReady to elevate your practice? This episode is sponsored by Fullscript, a comprehensive care delivery platform designed to support whole-person, integrative healthcare. Fullscript helps clinicians bring supplement dispensing, lab ordering, and patient education into one centralized workflow. For more practitioner education on supplements, nutrition, and evidence-informed clinical care, visit Fullscript Academy at academy.fullscript.com.Disclaimer: The views expressed on this podcast are those of the hosts and guests and don’t necessarily reflect those of Fullscript or any affiliated organizations. This podcast is for informational and educational purposes only and is not intended to be medical advice. For your safety, always check with your doctor or healthcare provider before making changes to your health routine.ReferencesDiener, C., Gibbons, S. M., & Resendis-Antonio, O. (2020). MICOM: Metagenome-scale modeling to infer metabolic interactions in the gut microbiota. mSystems, 5(1), Article e00606-19. https://journals.asm.org/doi/10.1128/msystems.00606-19Porcari, S., Mullish, B. H., Asnicar, F., Ng, S. C., Zhao, L., Hansen, R., O’Toole, P. W., Raes, J., Hold, G., Putignani, L., Hvas, C. L., Zeller, G., Koren, O., Tun, H., Valles-Colomer, M., Collado, M. C., Fischer, M., Allegretti, J., Iqbal, T., . . . Ianiro, G. (2025). International consensus statement on microbiome testing in clinical practice. The Lancet Gastroenterology & Hepatology, 10(2), 154–167. https://www.sciencedirect.com/science/article/abs/pii/S246812532400311XQuince, C., Walker, A. W., Simpson, J. T., Loman, N. J., & Segata, N. (2017). Shotgun metagenomics, from sampling to analysis. Nature Biotechnology, 35(9), 833–844. https://www.nature.com/articles/nbt.3935

Nov 5, 2026 • 33min
Resolving vs. Reducing Inflammation: What Clinicians Need to Know about SPMs
On the Root Cause Medicine Podcast, Dr. Lara Zakaria joins Dr. Malisa Carulo to explore specialized pro-resolving mediators (SPMs), omega-3-derived precursors, and emerging pain research, with a focus on evidence limits and clinical decision-making.Clinical TakeawaysDistinguish SPMs from their precursors. TSPMs are lipid signals that help steer inflammation toward resolution. (Serhan 2018) SPM-focused marine-oil supplements contain upstream intermediates, a few enzymatic steps closer to finished SPMs than EPA and DHA, but these are not equivalent to finished SPMs. (Souza 2020)Separate mechanisms from clinical outcomes. condition.Mechanistic research outpaces human trials, which so far center on pain and musculoskeletal conditions such as osteoarthritis. (Callan 2020) (Möller 2023) Evidence does not yet support broad benefits for autoimmune disease, gut health, or every inflammatory condition.Keep clinical response central. The conversation emphasizes pain, stiffness, and mobility alongside foundational care. Acute high-dose strategies and bedtime use are discussed as anecdotes, not validated protocols.GuestDr. Malisa Carulo holds a doctorate in naturopathic medicine and an MS in biology. Introduced as Senior Manager of Medical Information and Safety at Metagenics, her interests include chronic disease, healthy aging, and sports medicine.Clinician FAQ1. What are specialized pro-resolving mediators?SPMs, including resolvins, protectins, and maresins, as lipid signals involved in the active resolution of inflammation. (Serhan 2018)2. How do SPM-focused supplements differ from fish oil?The guest distinguishes EPA and DHA from downstream intermediates such as 18-HEPE, 17-HDHA, and 14-HDHA. This distinction alone does not establish superior clinical outcomes. (Möller 2023)3. What evidence for SPMs and joint pain does the episode discuss?The guest highlights early human research in musculoskeletal pain, including osteoarthritis, while acknowledging that clinical evidence remains limited relative to mechanistic research. (Callan 2020) (Möller 2023)4. Are SPM supplements established therapies for autoimmune or gut conditions?The discussion does not establish that use. The guest describes clinical experiences and biological hypotheses rather than condition-specific evidence sufficient to support broad treatment claims.5. Does the episode establish an SPM dosing protocol?No. Studies have used doses ranging from about 250 mg per day in early research to 500 mg and 1 g in human trials, but the guest cautions that evidence-guided dosing recommendations remain limited. (Callan 2020) (Möller 2023)Key Moments03:56 SPM biology and marine-oil intermediates07:42 Conversion pathways and inflammation resolution11:15 Mechanistic research versus human evidence13:21 Evaluating formulations and clinical outcomes18:44 Measurement limitations and pain research24:38 Dosing discussion and anecdotal strategies30:25 Tracking pain, stiffness, and mobilityDisclaimerThe views expressed on this podcast are those of the hosts and the guests, and they don't necessarily reflect the views of FullScript or any affiliated organizations. This podcast is for informational and educational purposes only, and it's not intended to be medical advice. For your safety, always check with your healthcare provider before making any changes to your healthcare routine.ReferencesCallan, N., Hanes, D., & Bradley, R. (2020). Early evidence of efficacy for orally administered SPM-enriched marine lipid fraction on quality of life and pain in a sample of adults with chronic pain. Journal of Translational Medicine, 18(1), Article 401. https://doi.org/10.1186/s12967-020-02569-5Möller, I., Rodas, G., Villalón, J. M., Rodas, J. A., Angulo, F., Martínez, N., & Vergés, J. (2023). Randomized, double-blind, placebo-controlled study to evaluate the effect of treatment with an SPMs-enriched oil on chronic pain and inflammation, functionality, and quality of life in patients with symptomatic knee osteoarthritis: GAUDI study. Journal of Translational Medicine, 21(1), Article 423. https://doi.org/10.1186/s12967-023-04283-4 Serhan, C. N., & Levy, B. D. (2018). Resolvins in inflammation: Emergence of the pro-resolving superfamily of mediators. Journal of Clinical Investigation, 128(7), 2657–2669. https://doi.org/10.1172/JCI97943Souza, P. R., Marques, R. M., Gomez, E. A., Colas, R. A., De Matteis, R., Zak, A., Patel, M., Collier, D. J., & Dalli, J. (2020). Enriched marine oil supplements increase peripheral blood specialized pro-resolving mediators concentrations and reprogram host immune responses: A randomized double-blind placebo-controlled study. Circulation Research, 126(1), 75–90. https://doi.org/10.1161/CIRCRESAHA.119.315506

Oct 29, 2026 • 51min
Depression, Nutrition, and Antidepressant Withdrawal: A Whole-Person Perspective
Dr. Kate Kresge is joined by psychiatrist James Greenblatt, MD, to discuss themes from his book Finally Hopeful, including nutrition, depression, laboratory assessment, and antidepressant withdrawal.Clinical TakeawaysDepression warrants a broad clinical assessment. Symptoms may overlap with medical conditions and nutritional deficiencies. (Bode 2021) (Lee 2020) (Bender 2017) The episode discusses thyroid function, iron, vitamin B12, folate, vitamin D, and other factors as part of a broader evaluation—not as universal causes of depression.Antidepressant discontinuation should be individualized. Abruptly stopping an antidepressant can cause withdrawal symptoms. (Henssler 2024) (Horowitz 2019) Gradual, clinician-supervised tapering is important; nutritional status may also be considered, although supplementation has not been established as a way to prevent withdrawal. (Horowitz 2019)Nutrition can be considered within whole-person mental healthcare. Protein, amino acids, omega-3 fatty acids, B vitamins, zinc, and magnesium are discussed. Testing and supplementation should reflect individual needs rather than assuming a common deficiency.Guest: James Greenblatt, MDJames Greenblatt, MD, is a psychiatrist and educator in integrative and functional psychiatry. He discusses a whole-person framework for evaluating depression, nutritional status, and antidepressant discontinuation.Clinician FAQ1. Can nutritional deficiencies contribute to depressive symptoms?Yes, nutritional status can be clinically relevant, but depression is multifactorial. (Bender 2017) (Malhi 2018) The episode discusses iron, vitamin B12, folate, vitamin D, zinc, and other nutrients clinicians may evaluate when appropriate.2. Why distinguish antidepressant withdrawal from depression?Withdrawal can occur when antidepressants are reduced or stopped, and symptoms may overlap with psychiatric symptoms. (Henssler 2024) (Horowitz 2019) Distinguishing withdrawal from recurrence of depression is important during discontinuation. (Horowitz 2019) 3. Should nutritional status be assessed before antidepressant tapering?The episode proposes evaluating nutritional status before and during tapering. Medication changes should be individualized and managed with the prescribing clinician.4. What role do amino acids play in mental health?Amino acids from dietary protein are precursors for many biologically important molecules, including neurotransmitters. (Tang 2025) The episode discusses amino acid assessment as part of Dr. Greenblatt’s clinical approach.5. Why screen for medical conditions in patients with depression?Some medical conditions may produce symptoms that resemble or coexist with depression. (Bode 2021) (Lee 2020) (Clappison 2020) The episode highlights thyroid disorders, anemia, and celiac disease as examples clinicians may investigate when clinically indicated.Key Moments03:44 Whole-person framework for depression07:46 Antidepressant withdrawal11:29 Nutritional assessment before tapering23:23 Amino acids and nutrition37:26 B vitamins and minerals46:15 Depression and celiac disease caseDisclaimerThe views expressed on this podcast are those of the hosts and the guests, and they don't necessarily reflect the views of Fullscript or any affiliated organizations. This podcast is for informational and educational purposes only, and it's not intended to be medical advice. For your safety, always check with your healthcare provider before making any changes to your healthcare routine.ReferencesBender, A., Hagan, K. E., & Kingston, N. (2017). The association of folate and depression: A meta-analysis. Journal of Psychiatric Research, 95, 9–18. https://doi.org/10.1016/j.jpsychires.2017.07.019Bode, H., Ivens, B., Bschor, T., Schwarzer, G., Henssler, J., & Baethge, C. (2021). Association of hypothyroidism and clinical depression: A systematic review and meta-analysis. JAMA Psychiatry, 78(12), 1375–1383. https://doi.org/10.1001/jamapsychiatry.2021.2506Clappison, E., Hadjivassiliou, M., & Zis, P. (2020). Psychiatric manifestations of coeliac disease, a systematic review and meta-analysis. Nutrients, 12(1), 142. https://doi.org/10.3390/nu12010142Henssler, J., Schmidt, Y., Schmidt, U., Schwarzer, G., Bschor, T., & Baethge, C. (2024). Incidence of antidepressant discontinuation symptoms: A systematic review and meta-analysis. The Lancet Psychiatry, 11(7), 526–535. https://doi.org/10.1016/S2215-0366(24)00133-0Horowitz, M. A., & Taylor, D. (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry, 6(6), 538–546. https://doi.org/10.1016/S2215-0366(19)30032-XLee, Y.-J., & Kim, H.-B. (2020). Association between anaemia and adult depression: A systematic review and meta-analysis of observational studies. Journal of Epidemiology and Community Health, 74(7), 565–572. https://doi.org/10.1136/jech-2020-213842Malhi, G. S., & Mann, J. J. (2018). Depression. The Lancet, 392(10161), 2299–2312. https://doi.org/10.1016/S0140-6736(18)31948-2Tang, J., Krushelnycky, L., Shaqo, A., & Cho, C. E. (2025). A comprehensive review of nutritional influences on the serotonergic system. Advances in Nutrition, 16(11), 100524. https://doi.org/10.1016/j.advnut.2025.100524

Oct 22, 2026 • 40min
First Aid Kit for Cold and Flu Season
Lara Zakaria, PharmD, MS, CNS, is a pharmacist and clinical nutritionist specializing in functional medicine and personalized nutrition. She explores what to do at the first sign of a cold or flu, from testing, rest, and hydration to zinc, vitamin C, elderberry, echinacea, honey, and kitchen remedies like garlic, ginger, turmeric, and green tea. She also covers zinc safety, copper balance, symptom relief, and when to seek care.

Oct 15, 2026 • 46min
Health Meets Wellness: The App and Dr. Edens’ Story
Health Meets Wellness: The App and Dr. Edens’ StoryDr. Elizabeth Sharp Edens is the founder of Health Meets Wellness, an integrative practice where every patient gets three plans: a medical plan, a movement plan and a nutrition plan. Guideline-based medicine is her North Star, and she layers in nutrition, yoga, herbal therapies and acupuncture, with dietitians on her team. It’s whole-person care built around how each patient actually lives.But she didn’t stop at the exam room. She’s spent three years building the Health Meets Wellness app to bring that same care to patients between visits, and to people far beyond her own practice. It features meal plans, photo food logging, an AI health coach, symptom tracking for patients on GLP-1s, yoga videos she filmed herself, and 20-minute, no-equipment strength workouts developed with a former Milwaukee Bucks performance lead. Now it’s being rebranded for women, with cycle tracking that adapts meal and exercise plans to each phase. There’s a free version, and practitioners can use it with their own patients.Elizabeth is double board-certified in internal medicine and obesity medicine, certified in functional medicine and a certified yoga instructor, and her path ran through Mount Sinai, a healthcare startup and One Medical. We talk about how she built her practice and her app without a tech background, why she became a yoga teacher, and how she supports patients on GLP-1s with movement and nutrition.If you love whole-person care but work in a hospital or conventional system without a roadmap, this one’s for you.Timestamps03:33 — What drew Dr. Elizabeth to medicine, and then to functional medicine08:15 — What her practice looks like today11:25 — From Mount Sinai to a startup to One Medical to her own practice14:14 — How to find opportunities beyond one-to-one care18:38 — Why she built an app, and why it’s designed for women25:54 — Advice if you’re not tech-savvy28:57 — Why she became a yoga teacher + fitting training into a full schedule32:25 — Metabolic health and what she sees as non-negotiable with GLP-1s35:41 — Movement on a GLP-1: building and measuring muscle at homeWant to elevate your practice? This episode is sponsored by Fullscript, a comprehensive care delivery platform designed to support whole-person, integrative healthcare. Fullscript allows clinicians to streamline supplement dispensing, lab ordering, and patient education in one free, centralized system—helping reduce administrative burden while supporting clinical decision-making. For practitioners, Fullscript offers access to professional-grade supplements, evidence-informed protocols, and lab integrations that can support more efficient planning and follow-up. For patients, it provides a clear, organized way to receive recommendations, manage refills, and stay engaged in their care. The goal is not to replace clinical judgment, but to make it easier for clinicians to focus on what matters most: thoughtful, individualized patient care.Disclaimer: The views expressed on this podcast are those of the hosts and guests and don’t necessarily reflect those of Fullscript or any affiliated organizations. This podcast is for informational and educational purposes only and is not intended to be medical advice. For your safety, always check with your doctor or healthcare provider before making changes to your health routine.

Oct 9, 2026 • 1h 5min
The Gut Ecosystem: An Update on How Keystone Species Shape the Microbiome
Dr. Oscar Coetzee joins Dr Lara Zakaria on the Root Cause Medicine Podcast to discuss emerging research on keystone commensal organisms and how microbial communities interact within the gut ecosystem.The conversation focuses on organisms including Akkermansia muciniphila, Faecalibacterium prausnitzii, Roseburia, Bifidobacterium longum, and Bifidobacterium adolescentis. Rather than viewing individual microbes in isolation, Dr. Coetzee describes an ecosystem model centered on cross-feeding, short-chain fatty acid production, and the intestinal environment.The episode also notes an important context: research on next-generation commensals is still developing, meaning findings from mechanistic studies, case reports, and early clinical research offer initial insights that complement rather than replace evidence from larger randomized controlled trials. (Jan 2024) (Kern 2026)Clinical takeawaysKeystone organisms are discussed as members of an interconnected ecosystem. The episode explores how organisms can produce metabolites or modify environmental conditions that may influence other members of the microbial community. (Belzer 2017) (Fusco 2023)Short-chain fatty acids are a major theme. Akkermansia, Faecalibacterium, and Roseburia are discussed in relation to acetate, propionate, and butyrate production and their potential roles within the intestinal environment. (Martin-Gallausiaux 2021) (Tingler 2025)Clinical evidence remains emerging. Dr. Coetzee describes early clinical observations and studies in progress, while the conversation acknowledges the need for additional published research, including controlled trials, before broader clinical conclusions can be drawn. (Jan 2024) (Kern 2026)Guest: Oscar Coetzee, PhD, DCNDr. Oscar Coetzee is Vice President of Clinical Education and Practitioner Support at Designs for Health. In the episode, he discusses his work in nutrition and microbiome research and his interest in next-generation commensal organisms.His discussion centers on moving beyond a single-organism view of probiotics toward understanding microbial communities, cross-feeding, and the environment in which commensal organisms coexist.Clinician FAQ1. What are keystone commensal organisms?They are microbes discussed for their potentially important roles within the broader gut ecosystem. (Rios Garza 2026)The episode focuses on how selected commensals interact with other organisms and their environment rather than evaluating them solely by abundance. (Banerjee 2018)2. Which organisms are discussed?The main organisms include Akkermansia muciniphila, Faecalibacterium prausnitzii, Roseburia, Bifidobacterium longum, and Bifidobacterium adolescentis.The conversation also discusses Anaerostipes caccae separately in the context of butyrate production and microbial cross-feeding. (Belzer 2017)3. What is microbial cross-feeding?Cross-feeding describes how metabolites produced by one organism can serve as substrates or influence conditions for another. (Culp 2023) (Louis 2017)The episode uses this concept to explain why microbial communities may be more informative than considering individual organisms in isolation. (Culp 2023)4. Why are short-chain fatty acids discussed?They are microbial metabolites that form part of the communication between gut microbes and their environment. (Martin-Gallausiaux 2021)The conversation highlights acetate, propionate, and butyrate while exploring how different commensal organisms contribute to their production. (Martin-Gallausiaux 2021)5. How established is the clinical evidence?Research on these next-generation commensals is still evolving. (Jan 2024) (Kern 2026)The guest describes case observations, prospective studies, and additional research underway. These early findings can generate hypotheses, but they do not establish that a specific probiotic combination prevents or treats disease.Timestamps / key moments00:00:00 Introducing keystone commensal organisms00:05:35 Why newer technology matters for anaerobic microbes00:08:09 Moving beyond probiotic quantity and individual strains00:13:32 Microbial compensation and ecosystem dynamics00:18:00 Keystone organisms and emerging clinical observations00:21:28 Akkermansia and microbial metabolites00:24:08 Faecalibacterium prausnitzii and butyrate00:30:49 Roseburia and the anaerobic environment00:32:24 Bifidobacterium species in the microbial community00:35:52 Anaerostipes caccae and cross-feeding00:39:58 Supporting the microbial ecosystem00:44:18 Current research and evidence limitations00:48:02 Clinical considerations and unanswered questions01:02:15 Future research and closing discussionWant to learn more about microbiome science?This episode highlights an evolving way of thinking about the microbiome: not simply as a collection of individual organisms, but as an ecosystem shaped by microbial interactions, metabolites, available substrates, and environmental conditions.For additional practitioner education on supplement quality and clinical decision-making, visit Fullscript Academy.DisclaimerThe views expressed on this podcast are those of the host and guest and do not necessarily reflect those of Fullscript or affiliated organizations.This episode is for informational and educational purposes only and is not medical advice. Research on next-generation commensal organisms and related probiotic formulations is evolving, and emerging findings should be interpreted in the context of the strength and limitations of the available evidence.ReferencesBanerjee, S., Schlaeppi, K., & van der Heijden, M. G. A. (2018). Keystone taxa as drivers of microbiome structure and functioning. Nature Reviews Microbiology, 16(9), 567–576. https://doi.org/10.1038/s41579-018-0024-1Belzer, C., Chia, L. W., Aalvink, S., Chamlagain, B., Piironen, V., Knol, J., & de Vos, W. M. (2017). Microbial metabolic networks at the mucus layer lead to diet-independent butyrate and vitamin B12 production by intestinal symbionts. mBio, 8(5), e00770-17. https://doi.org/10.1128/mBio.00770-17Culp, E. J., & Goodman, A. L. (2023). Cross-feeding in the gut microbiome: Ecology and mechanisms. Cell Host & Microbe, 31(4), 485–499. https://doi.org/10.1016/j.chom.2023.03.016Fusco, W., Lorenzo, M. B., Cintoni, M., Porcari, S., Rinninella, E., Kaitsas, F., Lener, E., Mele, M. C., Gasbarrini, A., Collado, M. C., Cammarota, G., & Ianiro, G. (2023). Short-chain fatty-acid-producing bacteria: Key components of the human gut microbiota. Nutrients, 15(9), 2211. https://doi.org/10.3390/nu15092211Jan, T., Negi, R., Sharma, B., Kumar, S., Singh, S., Rai, A. K., Shreaz, S., Rustagi, S., Chaudhary, N., Kaur, T., Kour, D., Sheikh, M. A., Kumar, K., Yadav, A. N., & Ahmed, N. (2024). Next generation probiotics for human health: An emerging perspective. Heliyon, 10(16), e35980. https://doi.org/10.1016/j.heliyon.2024.e35980Kern, L., Tofield, A., Frame, J., & Elinav, E. (2026). Next-generation probiotics: An outlook into current applications and future developments. Nature Reviews Microbiology, 24(8), 539–558. https://doi.org/10.1038/s41579-026-01311-0Louis, P., & Flint, H. J. (2017). Formation of propionate and butyrate by the human colonic microbiota. Environmental Microbiology, 19(1), 29–41. https://doi.org/10.1111/1462-2920.13589Martin-Gallausiaux, C., Marinelli, L., Blottière, H. M., Larraufie, P., & Lapaque, N. (2021). SCFA: Mechanisms and functional importance in the gut. Proceedings of the Nutrition Society, 80(1), 37–49. https://doi.org/10.1017/S0029665120006916Rios Garza, D., Gonze, D., & Faust, K. (2026). Keystone concept revisited: Insights into microbial community dynamics and control. Nature Reviews Microbiology, 24(5), 359–371. https://doi.org/10.1038/s41579-025-01266-8Tingler, A. M., & Engevik, M. A. (2025). Breaking down barriers: Is intestinal mucus degradation by Akkermansia muciniphila beneficial or harmful? Infection and Immunity, 93(9), e0050324. https://doi.org/10.1128/iai.00503-24

Oct 1, 2026 • 26min
Menopause Botanicals: Identity, Standardization & Patience
Dr. Eric Viegas, an Ottawa-based naturopathic doctor and supplement-quality specialist, explores how to choose menopause botanicals that match the research. He examines black cohosh, Vitex, rhapontic rhubarb, maca, and soy isoflavones, highlighting identity, extract standardization, product variability, and why meaningful evaluation takes patience.

Sep 24, 2026 • 56min
Meet the New Voices of the Root Cause Medicine Podcast
Meet the clinicians bringing fresh perspectives to root-cause medicine. They share personal journeys from pharmacy, psychology, nursing, and naturopathic care, plus the misdiagnosed illness that finally revealed the power of proper testing. Topics include fertility, nutrition credentials, professional advocacy, mental and physical health, and a new platform for labs, education, and evidence.

Sep 17, 2026 • 54min
C15:0, ferroptosis, and metabolic health: What practitioners should know
Stephanie Venn-Watson, a veterinary epidemiologist and comparative-medicine researcher, shares how aging bottlenose dolphins helped uncover C15:0. They explore its proposed role as an essential fatty acid, cell-membrane health, ferroptosis and iron-driven lipid damage, metabolic hyperferritinemia, fatty liver disease, dairy sources, and emerging supplementation research.


